^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + ImmuFact (eftilagimod alpha) (APC activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
Published date:
05/19/2021
Excerpt:
Thirty-five (35) pts were evaluated for response (cut-off Jan 2021) with 4 (11 %) pts showing CR, 7 (20 %) pts PR, 3 (9 %) pts SD, 16 (46 %) pts PD with 5 (14 %) pts being not evaluable as per iRECIST. ORR was reported with 31.4 % (95 % CI 16.9 % - 49.3 %) and DCR 40 %Median PFS was 2.1 months and 35 % were progression free at 6 months. Median OS (46 % events) was 12.6 months...Efti in combination with pembrolizumab is safe and shows encouraging antitumor activity in platinum pre-treated 2nd line HNSCC patients.
DOI:
10.1200/JCO.2021.39.15_suppl.6028
Trial ID:
Source:
Title:
790 A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)
Published date:
11/09/2020
Excerpt:
Pts from all PD-L1 tumor expression subgroups were recruited. Pts received a median of 4 (1-25) pembrolizumab and 5.5 (1-22) efti administrations….Efti plus pembrolizumab is safe and shows encouraging antitumor responses in NSCLC and HNSCC patients.
DOI:
10.1136/jitc-2020-SITC2020.0790
Source:
Title:
927P - Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients
Published date:
09/14/2020
Excerpt:
Pts from all PD-L1 subgroups (CPS < 1 %, 1-20%, ≥20 %) were recruited. Pts received a median of 5 pembrolizumab and 7 efti administrations. All pts in stage 1 (n=18) were evaluable. Six pts (33 %) had a partial response (iPR), 1 patient (6 %) had a complete response and 2 (11 %) had stable disease according to iRECIST representing an ORR (DCR) of 39 % (50 %). Threshold for opening stage 2 (> 2 responses) was met. Efti in combination with pembrolizumab is safe and shows encouraging antitumor activity in 2nd line HNSCC patients.
Trial ID:
Source:
Title:
Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab.
Published date:
05/13/2020
Excerpt:
Efti in combination with pembrolizumab is safe and shows encouraging antitumor activity in all comer PD-L1 1st line NSCLC and 2nd line HNSCC.
DOI:
10.1200/JCO.2020.38.15_suppl.3100
Trial ID:
